NAB-paclitaxel and gemcitabine in metastatic pancreatic ductal adenocarcinoma (PDAC): from clinical trials to clinical practice
Published 2016 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
NAB-paclitaxel and gemcitabine in metastatic pancreatic ductal adenocarcinoma (PDAC): from clinical trials to clinical practice
Authors
Keywords
Metastatic pancreatic cancer, Combination chemotherapy, Nab-paclitaxel, Gemcitabine
Journal
BMC CANCER
Volume 16, Issue 1, Pages -
Publisher
Springer Nature
Online
2016-09-02
DOI
10.1186/s12885-016-2671-9
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Cancer statistics, 2015
- (2015) Rebecca L. Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- nab-Paclitaxel Plus Gemcitabine for Metastatic Pancreatic Cancer: Long-Term Survival From a Phase III Trial
- (2015) D. Goldstein et al. JNCI-Journal of the National Cancer Institute
- nab-Paclitaxel Plus Gemcitabine for Metastatic Pancreatic Cancer: Long-Term Survival From a Phase III Trial
- (2015) D. Goldstein et al. JNCI-Journal of the National Cancer Institute
- Blood Neutrophil–Lymphocyte Ratio Predicts Survival in Patients with Advanced Pancreatic Cancer Treated with Chemotherapy
- (2014) Guopei Luo et al. ANNALS OF SURGICAL ONCOLOGY
- Prognostic value of systemic inflammation-based markers in advanced pancreatic cancer
- (2014) H. L. Martin et al. INTERNAL MEDICINE JOURNAL
- Second-Line Oxaliplatin, Folinic Acid, and Fluorouracil Versus Folinic Acid and Fluorouracil Alone for Gemcitabine-Refractory Pancreatic Cancer: Outcomes From the CONKO-003 Trial
- (2014) Helmut Oettle et al. JOURNAL OF CLINICAL ONCOLOGY
- Beyond first-line chemotherapy for advanced pancreatic cancer: An expanding array of therapeutic options?
- (2014) Evan J Walker WORLD JOURNAL OF GASTROENTEROLOGY
- Prognostic factors related with survival in patients with pancreatic adenocarcinoma
- (2014) Ahmet Bilici WORLD JOURNAL OF GASTROENTEROLOGY
- SPARC independent drug delivery and antitumour effects ofnab-paclitaxel in genetically engineered mice
- (2013) Albrecht Neesse et al. GUT
- Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine
- (2013) Daniel D. Von Hoff et al. NEW ENGLAND JOURNAL OF MEDICINE
- nab -Paclitaxel Potentiates Gemcitabine Activity by Reducing Cytidine Deaminase Levels in a Mouse Model of Pancreatic Cancer
- (2012) Kristopher K. Frese et al. Cancer Discovery
- Gemcitabine Plusnab-Paclitaxel Is an Active Regimen in Patients With Advanced Pancreatic Cancer: A Phase I/II Trial
- (2011) Daniel D. Von Hoff et al. JOURNAL OF CLINICAL ONCOLOGY
- Pancreatic cancer
- (2011) Audrey Vincent et al. LANCET
- FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer
- (2011) Thierry Conroy et al. NEW ENGLAND JOURNAL OF MEDICINE
- EUROCARE-4. Survival of cancer patients diagnosed in 1995–1999. Results and commentary
- (2009) Milena Sant et al. EUROPEAN JOURNAL OF CANCER
- Phase III Randomized Comparison of Gemcitabine Versus Gemcitabine Plus Capecitabine in Patients With Advanced Pancreatic Cancer
- (2009) David Cunningham et al. JOURNAL OF CLINICAL ONCOLOGY
- Tolerance and Efficacy of Gemcitabine and Gemcitabine-Based Regimens in Elderly Patients With Advanced Pancreatic Cancer
- (2009) Raphaël Maréchal et al. PANCREAS
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now